Selumetinib (AZD6244, ARRAY-142886) is a mitogen-activated protein kinase kinase inhibitor that has been tested for treatment of non-small cell lung cancer (NSCLC). Selumetinib (75 mg twice daily) plus docetaxel in patients with advanced NSCLC has been assessed in phase 2 (SELECT-2) and phase 3 (SELECT-1) clinical trials. The objective of the current analysis was to investigate the exposure-response relationship of selumetinib in these 2 clinical trials, based on the development of a population pharmacokinetic (PopPK) model for selumetinib and its active metabolite, N-desmethyl selumetinib, in patients with NSCLC. A PopPK model using data from seven phase 1 studies was first developed and served as prior information for the development of the patient PopPK model. The pharmacokinetics (PK) of selumetinib and N-desmethyl selumetinib were modeled simultaneously. A two-compartment model with zero-first order absorption and first-order elimination reasonably described the selumetinib PK. The N-desmethyl metabolite of selumetinib was described by a one-compartment model with first-order elimination. The final PK parameter estimates were similar between patients with NSCLC and patients in the phase 1 population. Selumetinib apparent clearance and central volume of distribution were 11.9 L/h and 32.1 L, respectively, in patients. Individual selumetinib exposure metrics were estimated to investigate the correlation between exposure and efficacy/safety endpoints observed in NSCLC studies. There was no significant difference in progression-free survival (the primary endpoint) among the different quartiles of exposure. Similarly, no significant correlation was observed between selumetinib exposure and other secondary efficacy or safety endpoints. The conclusions are in accordance with the reported clinical findings.
A number of molecular abnormalities have been linked to certain lung cancers. V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most common mutations in non-small lung cancer (NSCLC) associated with activation of the rat sarcomaextracellular signal-regulated kinase (RAS-ERK) signaling pathway that drives tumor growth. 1 First-line chemotherapy for advanced/metastatic NSCLC usually includes platinum-based doublet chemotherapy, which has been shown to prolong survival, improve quality of life, and control symptoms in patients. 2 Docetaxel and pemetrexed are standard chemotherapies recommended for second-line treatment of NSCLC, 3 and the programmed death protein 1 inhibitors pembrolizumab 4, 5 and nivolumab 6, 7 were approved in 2015 as novel immunotherapies for metastatic NSCLC. Selumetinib inhibits the activity of mitogenactivated protein kinase kinase (MEK) 1/2, which is a critical component of the RAS-ERK pathway. 8 It inhibits constitutive and cytokine-stimulated ERK phosphorylation in various tumor cell lines, as well as tumor growth in vivo in a human plasmacytoma xenograft model. 9 Selumetinib has also previously been shown to demonstrate time-dependent suppression of ERK phosphorylation, with the magnitude of suppression being generally related to selumetinib plasma concentrations in patients with advanced cancer. 10 Selumetinib has a short half-life (5-7 hours), and its pharmacokinetic (PK) profile is approximately doseproportional from 25 mg to 150 mg in patients with advanced cancer. 11 Cytochrome P450 (CYP) 1A2, 2C19, 3A4, and 3A5 are mainly responsible for the metabolism of selumetinib, with CYP1A2 being the enzyme primarily responsible for the formation of the N-desmethyl metabolite.
12,13 N-desmethyl selumetinib is metabolized through the same routes as the parent drug. In studies, selumetinib, N-desmethyl selumetinib, and glucuronide conjugates of both were the major components identified in human plasma, and the amide metabolite was also detected in human plasma.
12,13 N-desmethyl selumetinib is an active metabolite, and shows a 3-to 5-fold greater potency for MEK1 inhibition in vitro than the parent compound. N-desmethyl selumetinib has relative lower exposure in vivo, with area under the plasma-drug concentrationtime curve (AUC) and maximum concentration of drug in plasma (C max ) typically <10% of the parent compound. 10, 11 Selumetinib is currently in the development for various oncology indications, including differentiated thyroid cancer (NCT00559949) and neurofibromatosis type 1.
14 The dose for selumetinib monotherapy was 75 mg twice daily, 10, 15, 16 and a 75-mg twice-daily dose was also given to patients administered combination therapies. 1, [17] [18] [19] Combining selumetinib with chemotherapy has shown potential benefit in preclinical studies of tumor xenograft models, in which selumetinib in combination with cytotoxic agents showed enhanced tumor growth inhibition compared with selumetinib monotherapy or chemotherapy alone. 20 Selumetinib plus docetaxel in the treatment of patients with advanced NSCLC has been assessed in phase 2 (SELECT-2 21 [NCT01750281]) and phase 3 (SELECT-1 1, 17 [NCT01933932]). The objectives of these 2 studies were to assess the efficacy, safety, and tolerability of selumetinib combined with docetaxel compared to docetaxel alone as second-line therapy for advanced NSCLC. The majority of patients in SELECT-2 were KRAS-negative, whereas all patients in SELECT-1 were KRAS-positive. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and safety and tolerability. However, these randomized trials failed to meet the primary endpoint, ie, addition of selumetinib to docetaxel did not improve PFS compared with docetaxel alone. The most common adverse events (AEs) in the SELECT-2 and SELECT-1 treatment arms included diarrhea, nausea, rash, peripheral edema, and neutropenia. More serious AEs were reported in patients from the selumetinib treatment group compared with patients receiving docetaxel alone. 17, 21 The objectives of the current analysis were to 1) develop a population pharmacokinetic (PopPK) model of selumetinib and N-desmethyl selumetinib for patients with NSCLC from the SELECT-2 and SELECT-1 studies and 2) investigate the potential exposure-response relationship of selumetinib in the SELECT-2 and SELECT-1 trials using a quantitative modeling approach based on patients' PK and efficacy and safety data.
Method

PopPK Model Development
Study and Dataset. All studies were performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and were consistent with the International Conference on Harmonization/Good Clinical Practice applicable regulatory requirements and the AstraZeneca policy on bioethics. The clinical study protocol, informed consent form(s), and all other appropriate study-related documents were reviewed and approved by local independent ethics committees/institutional review boards.
Because of the sparse PK data for patients in the phase 2 and phase 3 studies, a PopPK model with data from seven phase 1 studies was first developed and served as prior information for the patient PopPK model. The seven phase 1 studies were study 69 (NCT01974349), study 71 (NCT02056392), study 78 (NCT02322749), study 80 (NCT02238782), study 81 (NCT02063204), study 83 (NCT02093728), and study 85 (NCT02046850). The patient PopPK dataset included patients from SELECT-2 andSELECT-1. The oral dose of selumetinib varied from 25 mg to 75 mg (majority) in the phase 1 studies, and all patients in the phase 2 and 3 studies received 75 mg twice daily as a starting dose. All phase 1, phase 2, and phase 3 studies included in this analysis used the same capsule formulation of selumetinib. Twelve subjects from study 80 (NCT02238782) received an intravenous injection microdose of [ 11 C]-labeled selumetinib. A summary of all the studies, including the dosing and sampling schedule, is presented in Table 1 .
Plasma concentrations of selumetinib and N-desmethyl selumetinib were determined using a validated liquid chromatography-tandem mass spectrometry method with appropriate precision and accuracy. 22 The linear calibration curve ranges for selumetinib and N-desmethyl selumetinib were 2-2000 ng/mL and 2-500 ng/mL, respectively. All plasma samples were stored at −20°C or lower until analysis.
PopPK Model for Phase 1 Population
The PopPK analysis was carried out using NONMEM (version 7.3.0, ICON, GloboMax; Hanover, Maryland). R version 3.2.2 (The R Foundation for Statistical Computing) was used for data preparation, graphical analysis, and postprocessing of NONMEM analysis. Guided by exploratory graphical analysis, the structural model was first tested by fitting a one-compartment or two-compartment model to the log-transformed selumetinib plasma concentration data. Different absorption models, including first-order absorption and a sequential zero-first order elimination model, were also tested. The model was then modified to incorporate 2 clearance routes, one for N-desmethyl selumetinib and the other for the rest of the metabolism. The disposition of N-desmethyl selumetinib was described by a onecompartment model with first-order elimination. The volume of distribution of N-desmethyl selumetinib was fixed to 1. 23 The potential interindividual variability (IIV) was evaluated in a stepwise manner for each parameter. The model was updated based on successful convergence of the model and changes in objective function value. A summary of the stepwise selection of IIV in the phase 1 model is presented in Supplemental Table S1 . The proportional residual variability was modeled as an additive error in the log domain and estimated separately for parent, metabolite, and intravenous injection subgroup data.
The covariate effects on the PK parameters were evaluated with a statistical hypothesis test of significance. The intrinsic and extrinsic factors, including age, body weight, sex, race, baseline liver function (alanine aminotransferase, alkaline phosphatase, bilirubin), baseline renal function (body surface area normalized baseline creatinine clearance), and baseline albumin were explored on relevant selumetinib PK parameters (Supplemental Table S2 ) in an automated forward inclusion followed by backward elimination procedure, using the stepwise covariate model tool as implemented in the Perl-speaks-NONMEM toolkit (Department of Pharmacy, Uppsala University, Uppsala, Sweden). 24 The selection criteria were defined as P < .05 for forward selection and P < .005 for backward elimination.
PopPK Model for Patient Population
The PopPK model for patient populations in the SELECT-2 and SELECT-1 studies was developed with a Bayesian approach 25, 26 using the phase 1 PopPK model as an informative prior. Informative prior provided distribution of parameters, with numerical information based on a previously established model, which was crucial to the estimation of the current model. Specifically, the structure of the patient PopPK model was defined to be the same as the phase 1 PopPK model, and the final PK parameter estimates and covariance matrix of estimates of the phase 1 model were used as the priors. The PK parameters of the patient population were then estimated by updating the prior distributions with the phase 2 and phase 3 patient dataset under the Bayesian framework. Because the patient PK dataset contained a large number of subjects (n = 371) but sparse sampling, much higher variability was observed than for the phase 1 PK data, therefore, the prior was not applied to the IIV of parameter estimates; IIV was instead estimated based on the patient dataset. The IIV was assigned to all PK parameters using a full model approach with possible backward elimination. Additive residual error in the log domain was estimated separately for selumetinib and N-desmethyl selumetinib. Inter-occasional variability was considered for clearance between the first cycle (21 days for 1 cycle) and the rest of the sampling time.
The modeling was conducted using the NONMEM 7.3.0 with $PRIOR subroutine, which employed the restricted maximum likelihood function for constraining parameter estimates based on prior knowledge. 26 Model estimation was based on a stochastic approximation expectation maximization method, with 2000 burn-in samples, 1000 iterations, and the ISAMPLE (the number of Monte Carlo samples per individual) rate equal to 5, in combination with importance sampling using expectation step (EONLY = 1). 27, 28 A Markov chain Monte Carlo technique was used to make inferences about posterior distributions of the parameters of interest.
Model Evaluation
Model evaluation was guided by several assessment methods, including visual inspection of diagnostic plots, successful convergence, changes in objective function value, precision of parameter estimates, and plausibility of parameter estimates. The final model of selumetinib and N-desmethyl selumetinib was evaluated using a nonparametric bootstrap approach with 1000 replicate bootstrap datasets. 24 The predictive performance of the final model was also assessed with prediction-corrected visual predictive check (pcVPC) by simulating 1000 datasets for each model. Bootstrap and pcVPC were performed using tools implemented in Perl-speaks-NONMEM. 24 Exposure-Response Analysis Individual empirical Bayes estimates of selumetinib PK parameters from the final patient PopPK model were used to predict the individual exposure of selumetinib and its metabolite. The actual dosing records of each patient, including dose reduction and interruption, were considered in the simulation. Dummy time points were generated for every 30 minutes within a 12-hour window after the last dosing time at steady state. The exposure in steady-state area under curve (AUC ss ), steady-state maximum concentration (C max,ss ), and steady-state minimum concentration (C trough,ss ) of selumetinib and N-desmethyl selumetinib were calculated using the simulated concentration at steady state during a 12-hour dosing interval. The correlation between the estimated selumetinib exposure and the efficacy or safety endpoints was assessed with exploratory graphical analysis. The investigated efficacy endpoints included PFS, OS, ORR; in SELECT-2, the duration of response and change in tumor size at week 6 were also included. Safety endpoints included 18 AEs: rash, rash dermatitis acneiform, oral mucositis, retinal events, interstitial lung disease effects, febrile neutropenia, neutropenia, erythropenia, cardiac failure, musclerelated effects, infections, transaminase and bilirubin elevations, incidence of investigation, vomiting, diarrhea, asthenia effects, peripheral edemas, and facial edemas. The relationship between exposure and dose interruption, dose reduction, and termination due to AE was also explored.
Results
The dataset for PK analysis included 213 subjects from the phase 1 studies and 371 subjects from the patient studies. The majority of the population was men (97.7% in the phase 1 studies; 66.3% in the patient studies) and white (59.2% in the phase 1 studies; 95.1% in the patient studies). The demographics of studied subjects across the phase 1 and patient populations are summarized in Table 2 . Overall, there were 4823 selumetinib and 3784 N-desmethyl selumetinib intense sampling plasma concentration measurements in the phase 1 studies and 1879 selumetinib and 1544 N-desmethyl selumetinib sparse concentration measurements in the patient BSA, body surface area. Age, body weight, BSA normalized creatinine clearance, and bilirubin are expressed as mean value and range (min-max) for each study. studies. Plasma concentrations below the limit of quantification were excluded from PK analysis. Approximately 4.3% and 11.4% of observations were flagged as after-dose limit of quantification for selumetinib and the N-desmethyl metabolite, respectively, in the phase 1 dataset and 1.3% and 3%, respectively, in the patient dataset.
PopPK Model for Phase 1 Population
A two-compartment model (reduced the objective function value by 919 compared with the one-compartment model) with sequential zero-first order absorption 29 and first-order elimination best described the PK of selumetinib; a one-compartment model with first-order elimination described the PK of N-desmethyl selumetinib. The scheme of the PopPK model is shown in Figure 1 . The food effect was conditioned on absorption PK parameters, including duration of absorption (D1), bioavailability (F1), and apparent first-order absorption rate constant (K a ). The effects of drug-drug interaction with rifampicin, fluconazole, and itraconazole on selumetinib clearance (CL) were also incorporated as categorical covariates in the base model. The IIV was added to selumetinib CL, central volume of distribution (V2), peripheral volume of distribution (V3), fraction of metabolite, F1, and lag time of absorption, using stepwise selection. Body weight was the only significant covariate identified for V2 in the phase 1 model. The PK parameter estimates of the final phase 1 model are shown in Supplemental Table S3 . Selumetinib CL was 12.0 L/h (coefficient of variation [CV%]: 14.8%) and N-desmethyl selumetinib CL was 16.6 L/h (CV%: 17.8). The fraction of metabolite was estimated to be 11%. The final parameter estimates were well within the 95% confidence intervals derived from the nonparametric bootstrap analysis (Supplemental Table S3 ). All parameters were estimated with reasonable precision, with shrinkage less than 25% for all parameters except high IIV (CV%: 103%) for duration of absorption, which was possibly due to high variability in the selumetinib absorption phase between subjects and across different studies.
Patient PopPK Model Based on Prior Information
The concentration-time profile of selumetinib and N-desmethyl selumetinib in the patient population showed similarity to that of the phase 1 healthy population (Supplemental Figure S1 ). Therefore, it was adequate to develop the patient PopPK model using the phase 1 final PopPK model as informative prior. The final PK parameter estimates of the patient population are shown in Table 3 ; the typical values of parameter estimates were similar to estimates in the phase 1 model. The clearance in the patient population was 11.9 L/h (CV%: 31.7%) and central volume of distribution was 32.1 L (CV%: 57.2%). The fraction of metabolite in patients was estimated to be 10.3% (CV%: 80.4%) and the clearance of metabolite was fixed to the phase 1 estimate (16.6 L/h). Bioavailability was assumed to be the same as that estimated in the phase 1 model (0.61). All patients were dosed under fasted condition, therefore no food effect was considered for the absorption of selumetinib in the patient model. There was a limited number of patients (<10% of total population) coadministered CYP3A or CYP2C19 inhibitors. In addition, the PK profiles were largely overlapping for patients with or without coadministration of CYP3A or CYP2C19 inhibitors, therefore, drug-drug interaction was not considered in the patient PopPK model. Based on the information from the phase 1 PopPK model, effect of body weight on V2 was included as a covariate in patient PopPK model. Other covariates were body weight, age, and sex on clearance; age and sex on V2 were also tested using exploratory plots. No significant trends were observed, therefore the body weight on V2 was considered the only significant covariate for the patient PopPK model. Compared with the results of phase 1 model (Supplemental Table S3 ), IIV in the patient model was much larger, especially for the V3, duration of absorption, and fraction of metabolite, which was probably due to the high variability and the sparse sampling nature of the patient data. The model was estimated with good precision, with reasonable shrinkage for all parameters except K a , which was 77.9%. This high shrinkage in K a was possibly due to the sparse nature of the patient data and insufficient number of samples collected during the absorption phase. Typical diagnostic plots for the final model of selumetinib and N-desmethyl selumetinib for the phase 2 and phase 3 patient data are shown in Supplemental Figure S2 , indicating adequate goodnessof-fit to the data. The pcVPC of the final patient model suggests that central tendency was reasonably predicted by the model (Figure 2) . The median values of parameters estimated from the bootstrap analysis were in good agreement with the population estimates in the final patient models, suggesting that the parameter estimates of the model were unbiased (Table 3) .
Exposure-Response Analysis
The individual steady-state exposure metrics of selumetinib and N-desmethyl selumetinib in the SELECT-2 and SELECT-1 treatment arms were estimated based on the final patient PopPK model. The geometric mean of the AUC ss (CV%) for selumetinib and N-desmethyl selumetinib was 4.3 μg·h/mL (38.4%) and 0.18 μg·h/mL (69.5%), respectively. The geometric mean of the C max,ss (CV%) for selumetinib and N-desmethyl selumetinib was 1.2 μg/mL (41.1%) and 0.051 μg/mL (79.6%), respectively. The median value of selumetinib AUC ss in patients was approximately the same level as that in the phase 1 studies (Supplemental Figure S3 ). The variability of selumetinib AUC ss in patients was much larger than that in phase 1 subjects, however, the range of AUC ss was mostly overlapping between the patient population and phase 1 subjects. In total, 371 subjects in the selumetinib treatment arm and 297 subjects in the control arm (docetaxel alone) from the patient studies, where selumetinib exposure was considered zero, were included in the exposureresponse analysis.
The Kaplan-Meier plots for the PFS primary endpoint and OS secondary endpoint in different exposure quartiles of selumetinib are shown in Figures 3A and B, respectively. There was no significant difference in PFS between different quartiles of AUC ss and the control group. Higher selumetinib exposure seems to have correlated with better OS, however, this trend was not clear due to the small number of subjects in each exposure quartile group after 20 months (<10% of population) and the overlapping OS curve of the control arm with different quartiles of the selumetinib treatment arm. For the metabolite N-desmethyl selumetinib, no significant difference was found for either PFS or OS for different quartiles of AUC ss (Supplemental Figure S4) . The correlation between selumetinib exposure and ORR was also assessed and is presented in Figure 4 . Eighty-five patients in the control arm and 41 patients in the selumetinib treatment arm were responders, and selumetinib exposure in responder group versus the nonresponder group was largely overlapping, with no significant difference in selumetinib exposure between responders and nonresponders ( Figure 4) . The plots with different C max,ss quartiles showed similar no significant trend (data not shown).
In terms of exposure versus safety endpoints, patients had categorical AE information recorded as a function of Common Terminology Criteria grade. Individual maximum Common Terminology Criteria grade during the study was used as the categorical endpoint. Ordered categorical AEs were represented as 0 for no event and 1, 2, 3, and 4 for mild, moderate, severe, and life-threatening, respectively. Diarrhea, rash, and neutropenia were among the most common AEs observed with selumetinib treatment. Exploratory graphical analyses of these AEs versus selumetinib exposure compared with controls were conducted. Figure 5 shows such stacked proportional bar charts for neutropenia at different selumetinib AUC ss and C max,ss , stratified by exposure quartiles. The percentage of subjects having the maximum grade of neutropenia revealed no trend across different quartiles of selumetinib exposure. There was also no apparent relation between selumetinib or N-desmethyl selumetinib exposure and the observed maximum grade of other AEs.
The C trough,ss was correlated with AUC ss , and similar results were observed in exposure-response analysis with C trough,ss (data on file). Overall, based on the above exploratory exposure-response analysis, no significant correlation was found between selumetinib exposure and efficacy and safety endpoints in SELECT-2 and SELECT-1 studies. Consequently, no further extensive pharmacokinetic/pharmacodynamic modeling was pursued.
Discussion
In the present study, a two-compartment model with sequential zero-first order absorption and first-order elimination adequately described the selumetinib PK, and a one-compartment model with first-order elimination was used to describe the N-desmethyl selumetinib PK. In a previous analysis, the PopPK of selumetinib and N-desmethyl selumetinib were characterized in pediatric patients and patients with advanced solid tumors using a sequential approach, where parent and metabolite data were modeled separately. 27 Another analysis modeled selumetinib and metabolite simultaneously, however, using only data from phase 1 studies. 23 The current analysis modeled PK for selumetinib and its active metabolite N-desmethyl selumetinib simultaneously in a population of patients with NSCLC using the phase 1 model as informative prior. The clearance, volume of distribution of central compartment, and volume of distribution of peripheral compartment in this population of patients with NSCLC was estimated to be 11.9 L/h, 32.1 L, and 54.0 L, respectively, which were close to the phase 1 PopPK estimates (12.0 L/h, 33.7 L, and 52.1 L, respectively). These values were also in close agreement with values reported in the previous phase 1 PopPK analysis (12.6 L/h, 35.6 L, and 47.4 L, respectively). 23 A comparison of the current PopPK model with 2 previously published models for selumetinib 23, 27 is presented in Supplemental  Table S4 . The PK of N-desmethyl selumetinib were reasonably described with addition of one metabolite compartment, and the conversion from selumetinib to metabolite served as input for this metabolite compartment. The fraction of metabolite for N-desmethyl was estimated to be 10.3% in patients, which was consistent with that reported previously, 11, 23 as well as that reported using noncompartmental analysis (average was approximately 10%; data on file). The estimated bioavailability of 61% from the current analysis was also similar to that reported in the absolute bioavailability study (62.1%; 90%CI, 60.1-64.1 [NCT 01974349]).
The PopPK model of the patient population was developed using a Bayesian approach and the phase 1 model estimation as informative prior. The main reason for using priors for the patient model was the sparse sampling dataset, thus, lack of information to independently describe the full PK characteristics of selumetinib and N-desmethyl selumetinib in the patient population, whereas the PK of selumetinib and metabolite were adequately described in the phase 1 population. Implementation of a Bayesian approach for the analysis allowed the posterior distribution of the patient PK parameters to be estimated, conditional on informative priors. The choice to use informative prior rather than noninformative prior provided necessary PK information to the sparse patient data, where the data might otherwise have provided inappropriate inferences. In addition, the demographic distribution of the patient population (Table 2 ) was similar to that of the phase 1 subjects except for age. As body weight was the only significant covariate in the phase 1 model, the PK parameter estimates in patients were likely to exhibit similarity compared with those in the phase 1 subjects. The effect of body weight on central volume of distribution was predefined as a covariate in the patient PK model. Although the relative standard error of central volume of distribution was very large (95.9%), removing this covariate from the patient model resulted in a significant increase in residual error and shrinkage. Therefore, the effect of body weight on central volume of distribution was kept as covariate in the patient model. In addition, the long computational running time for the combined phase 1 and patient dataset was also a concern. One preliminary attempt with combined phase 1 and patient datasets showed the parameter estimates were similar to the model using informative prior. All these analyses suggest the final PopPK model in patients adequately described patient PK and can be used for further exposure-response analysis.
Individual exposures of selumetinib and Ndesmethyl selumetinib in the SELECT-2 and SELECT-1 treatment arms were estimated based on the final patient PopPK model and were subsequently used in the exposure-response analysis. However, no significant difference was found between the exposure groups and the control arm for the primary endpoint of PFS (Figure 3 ). This conclusion is in accordance with the findings of the clinical studies: both studies failed, where selumetinib in combination with docetaxel did not show significant advantage compared to control arm docetaxel alone. For all other efficacy and safety endpoints evaluated, no noticeable relationship to selumetinib exposure was observed, which is similar to the result from the previous PK-safety analysis for selumetinib in combination with dacarbazine (NCT01974752). 19 This is possibly related to the fact that the SELECT-2 and SELECT-1 trials were both limited to the 75-mg twice-daily dose regimen. The available data might not have been sensitive enough to capture a significant exposure-response relationship if it presented. In addition, selumetinib failed to demonstrate clinical significance in both patient studies, which might also be the reason for the lack of exposure-response in this analysis. However, using a single starting dose is typical in oncology clinical trials, and current data could potentially be combined with other selumetinib studies of different starting doses in future PK analyses in order to extend the exposure range for a more significant exposure-response relation.
The exposure-response analysis could be further explored using a case control approach 30 to address potential confounding factors, however, because selumetinib in combination with docetaxel did not show significant advantage to docetaxel alone in the SELECT-2 and SELECT-1 studies, no further analysis was pursued. The current analysis used exposure metrics for the last PK day at steady state, so it may have only reflected the exposure of that particular day. Relating this steady-state exposure to, eg, a patient's maximum AE grade, which might occur afterward, could potentially bias the analysis. Using an exposure metric on the day the maximum grade AE occurred could potentially provide a more accurate assessment.
The current PK analysis helped to retrospectively investigate the relationship between selumetinib PK exposure and efficacy and safety in the SELECT-2 and SELECT-1 studies. In comparing the PopPK of selumetinib with another MEK inhibitor, trametinib, the PK of both drugs could be described by a twocompartment model, with no significant effect of renal function on clearance. Similar to selumetinib, body weight was also identified as one significant covariate for the PK of trametinib. 31 In addition, disease stage was found to be a significant predictor of response to trametinib in patients with advanced melanoma. However, no significant exposure-response relationship was identified in this phase 3 trametinib study. 31 In summary, the PK of selumetinib and N-desmethyl selumetinib in patients with advanced NSCLC was adequately described by a two-compartment model with sequential zero-first order absorption and firstorder elimination for the parent compound and a onecompartment model with first-order elimination for the metabolite. Exposure-response analysis revealed no significant relationship between selumetinib exposure and efficacy or safety endpoints, which was in accordance with the clinical findings of the phase 2 and phase 3 trials (SELECT-2 and SELECT-1). The modeling framework presented here could potentially be applied to guide future clinical development of selumetinib in NSCLC and other oncology indications.
